Image-guided hypofractionated double-scattering proton therapy in the management of centrally-located early-stage non-small cell lung cancer

References

• Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019;20(4):494–503.
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Hu C, Michalski J, et al. Long-term results of RTOG 0236: a phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage i non-small cell lung cancer. Int J Radiat Oncol. 2014;90(1):S30.
   Web of Science ®Google Scholar
• Haasbeek CJ, Lagerwaard FJ, Antonisse ME, et al. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer. 2010;116(2):406–414.
   PubMed Web of Science ®Google Scholar
• van der Voort van Zyp NC, Prevost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91(3):296–300.
   PubMed Web of Science ®Google Scholar
• Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. JCO. 2006;24(30):4833–4839.
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009;75(3):677–682.
   PubMed Web of Science ®Google Scholar
• Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65(4):1087–1096.
   PubMed Web of Science ®Google Scholar
• Hoppe BS, Huh S, Flampouri S, et al. Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy. Radiother Oncol. 2010;97(3):425–430.
   PubMed Web of Science ®Google Scholar
• Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. JCO. 2019;37(15):1316–1325.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). 2010. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
   Google Scholar
• Senthi S, Haasbeek CJ, Slotman BJ, et al. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol. 2013;106(3):276–282.
   PubMed Web of Science ®Google Scholar
• Tekatli H, Senan S, Dahele M, et al. Stereotactic ablative radiotherapy (SABR) for central lung tumors: plan quality and long-term clinical outcomes. Radiother Oncol. 2015;117(1):64–70.
   PubMed Web of Science ®Google Scholar
• Tekatli H, Haasbeek N, Dahele M, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with ‘ultracentral’ non-small cell lung cancer. J Thorac Oncol. 2016;11(7):1081–1089.
   PubMed Web of Science ®Google Scholar
• Georg D, Hillbrand M, Stock M, et al. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol. 2008;88(3):368–375.
   PubMed Web of Science ®Google Scholar
• Peeters A, Grutters JP, Pijls-Johannesma M, et al. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol. 2010;95(1):45–53.
   PubMed Web of Science ®Google Scholar
• Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e299–303.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors. Radiother Oncol. 2012;102(3):383–387.
   PubMed Web of Science ®Google Scholar
• Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013;86(5):964–968.
   PubMed Web of Science ®Google Scholar
• Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a ‘no fly zone. Int J Radiat Oncol Biol Phys. 2014;88(5):1120–1128.
   PubMed Web of Science ®Google Scholar
• Modh A, Rimner A, Williams E, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014;90(5):1168–1176.
   PubMed Web of Science ®Google Scholar
• Park HS, Harder EM, Mancini BR, et al. Central versus peripheral tumor location: influence on survival, local control, and toxicity following stereotactic body radiotherapy for primary non-small-cell lung cancer. J Thorac Oncol. 2015;10(5):832–837.
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Tang C, Binkley MS, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer. 2015;89(1):50–56.
   PubMed Web of Science ®Google Scholar
• Schanne DH, Nestle U, Allgauer M, et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol. 2015;191(2):125–132.
   PubMed Web of Science ®Google Scholar
• Ma SJ, Syed YA, Rivers CI, et al. Comparison of single- and five-fraction schedules of stereotactic body radiation therapy for central lung tumours: a single institution experience. J Radiother Pract. 2017;16(2):148–154.
   PubMed Web of Science ®Google Scholar
• Verma V, Shostrom VK, Zhen W, et al. Influence of fractionation scheme and tumor location on toxicities after stereotactic body radiation therapy for large (>/=5 cm) non-small cell lung cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;97(4):778–785.
   PubMed Web of Science ®Google Scholar
• Lindberg K, Bergström P, Brustugun OT, et al. OA24.05 The Nordic HILUS-Trial – first report of a phase II trial of SBRT of centrally located lung tumors. J Thoracic Oncol. 2017;12(1):S340.
   Web of Science ®Google Scholar
• Ono T, Yabuuchi T, Nakamura T, et al. High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer. Radiol Oncol. 2017;51(3):324–330.
   PubMed Web of Science ®Google Scholar
• Nantavithya C, Gomez DR, Wei X, et al. Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2018;101(3):558–563.
   PubMed Web of Science ®Google Scholar